Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate

被引:38
|
作者
Gamsjaeger, Sonja [1 ]
Buchinger, Birgit [1 ]
Zoehrer, Ruth [1 ]
Phipps, Roger [2 ]
Klaushofer, Klaus [1 ]
Paschalis, Eleftherios P. [1 ]
机构
[1] Hanusch Hosp, Ludwig Boltzmann Inst Osteol, WGKK & AUVA Trauma Ctr Meidling, Dept Med 1, A-1140 Vienna, Austria
[2] Procter & Gamble Pharmaceut, Mason, OH USA
关键词
Teriparatide; Alendronate; Risedronate; Bone material properties; Fourier transform infrared imaging; Raman Microspectroscopy; Mineral maturity; Collagen cross-links; ILIAC CREST BIOPSIES; FTIR MICROSPECTROSCOPIC ANALYSIS; PARATHYROID-HORMONE; AMERICAN-SOCIETY; MINERAL DENSITY; TASK-FORCE; QUALITY; OSTEONECROSIS; JAW; HYDROXYAPATITE;
D O I
10.1016/j.bone.2011.08.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the present work we examined the effect of teriparatide administration following bisphosphonate treatment on bone compositional properties by Raman and Fourier Transform Infrared Imaging (FTIR) microspectroscopic analysis. Thirty two paired iliac crest biopsies (before and after 1 year teriparatide) from sixteen osteoporotic women previously treated with either Alendronate (ALN) or Risedronate (RIS) and subsequently treated 12 months with teriparatide (TPTD) were analyzed at anatomical areas of similar tissue age in bone forming areas (within the fluorescent double labels). The outcomes that were monitored and reported were mineral to matrix ratio (corresponding to ash weight), mineral maturity (indicative of the mineral crystallite chemistry and stoichiometry, and having a direct bearing on crystallite shape and size), relative proteoglycan content (regulating mineralization commencement), and the ratio of two of the major enzymatic collagen cross-links (pyridinoline/divalent). Significant differences in mineral/matrix, mineral maturity/crystallinity, and collagen cross-link ratio bone quality indices after TPTD treatment were observed, indicating a specific response of these patients to TPTD treatment. Moreover differences between ALN and RIS treated patients at baseline in the collagen cross-link ratio were observed. Since tissue areas of similar tissue age were analyzed, these differences may not be attributed to differences in bone turnover. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1160 / 1165
页数:6
相关论文
共 50 条
  • [21] Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study
    Takahashi, Ryosuke
    Chiba, Ko
    Okazaki, Narihiro
    Era, Makoto
    Yokota, Kazuaki
    Yabe, Yoshihiro
    Kondo, Choko
    Fukuda, Toru
    Fukushima, Kaisho
    Kono, Mika
    Michikoshi, Yasue
    Yamada, Shuta
    Iida, Takeshi
    Mitsumizo, Kazutaka
    Sato, Shuntaro
    Doi, Mitsuru
    Watanabe, Kounosuke
    Ota, Shingo
    Shiraishi, Kazuteru
    Yonekura, Akihiko
    Osaki, Makoto
    BONE, 2024, 187
  • [22] Effects of two years treatment with teriparatide on bone mineral density in women with postmenopausal osteoporosis previously treated with anti-resorptive agents
    Michaud, M.
    CAHIERS DE L ANNEE GERONTOLOGIQUE, 2010, 2 (03): : 159 - 162
  • [23] Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
    N. Hassler
    S. Gamsjaeger
    B. Hofstetter
    W. Brozek
    K. Klaushofer
    E. P. Paschalis
    Osteoporosis International, 2015, 26 : 339 - 352
  • [24] Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate
    Durchschlag, Erich
    Paschalis, Eleftherios P.
    Zoehrer, Ruth
    Roschger, Paul
    Fratzl, Peter
    Recker, Robert
    Phipps, Roger
    Klaushofer, Klaus
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (10) : 1581 - 1590
  • [25] Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate
    Seibel, MJ
    Naganathan, V
    Barton, I
    Grauer, A
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (02) : 323 - 329
  • [26] Bone Material Quality in Transiliac Bone Biopsies of Postmenopausal Osteoporotic Women After 3 Years of Strontium Ranelate Treatment
    Roschger, Paul
    Manjubala, Inderchand
    Zoeger, Norbert
    Meirer, Florian
    Simon, Rolf
    Li, Chenghao
    Fratzl-Zelman, Nadia
    Misof, Barbara M.
    Paschalis, Eleftherios P.
    Streli, Christina
    Fratzl, Peter
    Klaushofer, Klaus
    JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (04) : 891 - 900
  • [27] Effects of Alendronate and Calcitonin on Bone Mineral Density in Postmenopausal Osteoporotic Women. An Observational Study
    Miroslava Hejdova
    Vladimir Palicka
    Zdenek Kucera
    Jiri Vlcek
    Pharmacy World and Science, 2005, 27 : 149 - 153
  • [28] Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study
    Hejdova, M
    Palicka, V
    Kucera, Z
    Vlcek, J
    PHARMACY WORLD & SCIENCE, 2005, 27 (03): : 149 - 153
  • [29] Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body
    Chevalier, Yan
    Quek, Evelyn
    Borah, Babul
    Gross, Gary
    Stewart, John
    Lang, Thomas
    Zysset, Philippe
    BONE, 2010, 46 (01) : 41 - 48
  • [30] Quality of life of postmenopausal women with teriparatide, denosumab and alendronate: One-year prospective study with a propensity score-matched comparison
    Lam, Pun Yuet
    Cheung, Prudence Wing Hang
    Lau, Sin Ting
    Cheung, Jason Pui Yin
    JOURNAL OF ORTHOPAEDICS TRAUMA AND REHABILITATION, 2023, 30 (01)